Thromboprophylaxis is the preventive use of medications, devices, or both to stop blood clots from forming in your veins. It targets two specific conditions collectively known as venous thromboembolism (VTE): deep vein thrombosis, where a clot forms in a deep vein (usually in the leg), and pulmonary embolism, where a clot breaks free and travels to the lungs. Pulmonary embolism can be life-threatening, and since most lung clots originate from leg veins, preventing clots at the source is the core goal.
How Blood Clots Form and Why Prevention Matters
Blood clots in deep veins develop when two things go wrong: blood flow slows down (venous stasis) and the blood itself becomes more prone to clotting (hypercoagulability). Situations that trigger one or both of these problems include surgery, prolonged bed rest, cancer treatment, serious infections, and heart failure. Without preventive measures, hospitalized patients facing these risk factors have a meaningfully higher chance of developing a clot that could travel to the lungs.
Thromboprophylaxis works by addressing one or both of those triggers. Medications reduce the blood’s tendency to clot. Mechanical devices keep blood moving through the veins. In many clinical settings, both approaches are used together.
Medication-Based Prevention
The most common pharmacological approach uses injectable blood thinners, particularly a class of drugs called low-molecular-weight heparins. These are given as a small injection under the skin, typically once or twice daily. An older form of heparin, given in lower doses, is also used, though it carries a somewhat higher risk of side effects. In recent years, newer oral blood thinners have become standard options as well, particularly after joint replacement surgery. These are taken as pills, which many patients find more convenient.
Aspirin also plays a role in certain situations. Some guidelines now include it as an acceptable option after hip or knee replacement, either alone or following an initial course of an injectable blood thinner.
Mechanical Devices
When blood thinners are too risky or need to be supplemented, mechanical methods step in. The two main devices are intermittent pneumatic compression sleeves and graduated compression stockings.
- Intermittent pneumatic compression sleeves are inflatable wraps placed around the legs that rhythmically squeeze and release, mimicking the natural pumping action of your calf muscles. This promotes pulsatile blood flow through the deep veins and also stimulates the body’s own clot-dissolving activity.
- Graduated compression stockings apply steady pressure that is tightest at the ankle and gradually decreases up the leg. This increases the speed and volume of blood flowing through the deep veins, reducing the pooling that leads to clot formation.
Mechanical devices carry a lower bleeding risk than medications, roughly 2.6% compared to 4.7% in trauma patients. They are often the first choice for people who cannot safely take blood thinners.
Who Needs It
Not every hospital patient requires thromboprophylaxis. Doctors use standardized scoring systems to sort patients by risk level. Two of the most widely used are the Caprini score and the Padua score. The Caprini system assigns points across multiple risk categories: 0 to 1 points is low risk, 2 points is moderate, 3 to 4 is high, and above 4 is the highest risk tier. The Padua score is simpler, drawing a single line at 4 points, with anything at or above that threshold considered high risk.
The factors that push scores higher include age over 70, a previous blood clot, reduced mobility, active cancer, recent heart attack or stroke, heart failure, and acute infection. Current guidelines recommend that all hospitalized patients be assessed for clot risk, with prophylaxis offered to those whose scores warrant it.
Cancer Patients and Clot Risk
Cancer significantly raises clot risk, but the picture varies widely between individual patients. According to guidelines from the American Society of Clinical Oncology, most hospitalized cancer patients with an acute medical illness need thromboprophylaxis throughout their hospital stay. For outpatients receiving chemotherapy, the decision is more nuanced. Routine prophylaxis is not recommended for all cancer outpatients, but clinicians may offer oral blood thinners or injectable options to selected high-risk individuals. Risk is assessed using the Khorana score, a validated tool that accounts for cancer type and other variables.
Oncology teams are also encouraged to educate patients about clot risk during high-risk periods, including major surgery, hospitalization, and active chemotherapy treatment.
Duration After Surgery
After major orthopedic surgery, thromboprophylaxis typically continues well beyond the hospital stay. For total hip or knee replacement, current guidelines recommend at least 10 to 14 days of prevention, with many protocols extending up to 35 days. The extended duration reflects the fact that clot risk remains elevated for weeks after these procedures, not just during the immediate recovery period.
Specific protocols vary. After hip replacement, one common approach involves injectable blood thinners for the first 10 days followed by aspirin for an additional period, bringing total coverage to about 28 days. After knee replacement, the minimum is generally 14 days. Some newer oral blood thinners are approved for these post-surgical windows as well.
Risks and Side Effects
The primary concern with any blood-thinning prophylaxis is bleeding. In trauma patients, the pooled risk of clinically significant bleeding sits around 3.9%. “Major bleeding” in this context means a drop in hemoglobin requiring a blood transfusion, bleeding that needs surgical intervention, or bleeding into the brain or abdomen. Importantly, no episodes of fatal bleeding were reported in studies using low-molecular-weight heparins for prophylaxis.
A less common but serious complication is heparin-induced thrombocytopenia (HIT), an immune reaction that paradoxically causes the platelet count to drop and can trigger new clots. The risk differs substantially by drug type. With low-molecular-weight heparins, the rate is very low, around 0% to 0.6% in studies. With older unfractionated heparin, the rate is considerably higher, ranging from 2.7% to 4.8%. This difference is one reason newer heparin formulations are generally preferred.
When Blood Thinners Cannot Be Used
Certain conditions make pharmacological prophylaxis too dangerous. Absolute contraindications include active bleeding, a known history of heparin-induced thrombocytopenia, very low platelet counts (below 50 billion per liter), severe liver disease with impaired clotting, and known drug allergy. Relative contraindications, where the decision requires careful weighing of risks, include recent brain hemorrhage, recent brain or eye surgery, gastrointestinal bleeding within the past month, active brain tumors, and dangerously high blood pressure.
In these situations, mechanical prophylaxis with compression devices becomes the primary strategy. Once the contraindication resolves, such as when active bleeding stops, pharmacological prophylaxis can often be started or resumed.